No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PRCT240517P32500
- 0.60
- 0.000.00%
15min DelayTrading Apr 4 12:14 ET
0.00High0.00Low
0.00Open0.60Pre Close0 Volume750 Open Interest32.50Strike Price0.00Turnover311.53%IV-49.98%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.60Time Value100Contract SizeAmericanOptions Type-0.0430Delta0.0032Gamma106.29Leverage Ratio-0.1638Theta-0.0007Rho-4.57Eff Leverage0.0084Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Raises Price Target to $75
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $67 to $75.
Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (PRCT), Springworks Therapeutics (SWTX) and Omnicell (OMCL)